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Summary 
Background: 
Chronic established pain, especially that following nerve injury, is difficult to treat and 
represents a largely unmet therapeutic need.  New insights are urgently required and 
we reasoned that endogenous processes such as cooling-induced analgesia may 
point the way to novel strategies for intervention.  Molecular receptors for cooling 
have been identified in sensory nerves and we demonstrate here how activation of 
one of these, TRPM8, produces profound, mechanistically novel, analgesia in chronic 
pain states. 
Results: 
We show that activation of TRPM8 in a subpopulation of sensory afferents (by either 
cutaneous or intrathecal application of specific pharmacological agents or by modest 
cooling) elicits analgesia in neuropathic and other chronic pain models in rats, 
inhibiting the characteristic sensitisation of dorsal horn neurons and behavioural 
reflex facilitation. TRPM8 expression was increased in a subset of sensory neurons 
after nerve injury. The essential role of TRPM8 in suppression of sensitised pain 
responses was corroborated by specific knockdown of its expression after intrathecal 
application of antisense oligonucleotide. We further show that the analgesic effect of 
TRPM8 activation is centrally mediated and relies on Group II/III metabotropic 
glutamate receptors (mGluRs), but not opioid receptors. We propose a scheme in 
which Group II/III mGluRs would respond to glutamate released from TRPM8-
containing afferents to exert an inhibitory gate control over nociceptive inputs.   
Please cite this article as: Proudfoot, CJ, Garry, EM, Cottrell, DF, Rosie, R, Anderson, H, Robertson, DC, Fleetwood-
Walker, SM & Mitchell, R  'Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain' Current biology 
2006, DOI: 10.1016/j.cub.2006.07.061
Conclusions: TRPM8 and its central downstream mediators, as elements of 
endogenous cooling-induced analgesia, represent a novel analgesic axis that can be 
exploited in chronic sensitised pain states. 
 
Introduction 
 
Chronic neuropathic pain arising from peripheral nerve damage is a severe 
clinical problem with limited treatment options[1]. Changes in both damaged and 
undamaged primary afferent neurons as well as central (spinal cord) sensitisation 
lead to hyperalgesia (accentuated responses to painful stimuli), allodynia (pain in 
response to normally innocuous stimuli) and spontaneous pain. We hypothesised 
that elucidating the poorly understood mechanisms underlying cold-induced 
analgesia might lead the way to novel neuropathic analgesics. 
 
Since Hippocrates and Galen[2,3], sporadic reports have described the use of 
cooling to produce analgesia[4]. Clinical trials show beneficial effects of cooling on 
chronic back pain, dental pain, post-operative pain, and muscle injuries[5]. 
Preparations containing menthol, which produces a cool sensation, are used topically 
to relieve neuralgia in traditional Chinese and European medicine[6,7]. Mint oil has 
been reported to alleviate thermally-elicited pain and post-herpetic neuralgia[8,9] and 
oral menthol can cause short-term analgesia[10]. Furthermore, in mice, oral or 
intracerebroventricular application of menthol decreased nociceptive responses to 
the hot-plate test and acetic acid writhing test[11].  Despite this history, no definitive 
mechanism has been established for cool-induced analgesia.  
 
The recent isolation of the TRP (transient receptor potential) cation channels 
present in primary sensory neurons has revolutionised our understanding of 
cutaneous temperature detection. The best characterised example is the capsaicin- 
and heat-sensitive TRPV1 receptor[12] and although much less is known about cool-
sensitive TRPs, they are the target of intensive research[13]. TRPM8 is activated at 
innocuous cool temperatures (with 50% activation around 18-19oC[14]) and by 
menthol and icilin[15,16], which act as selective (but not totally specific) activators of the 
channel[14,45]. The TRPM8 channel is expressed by a subpopulation of sensory 
neurons in dorsal root (DRG) and trigeminal ganglia[15,16] where responses to cooling 
correlate well with mRNA expression and menthol sensitivity[17,18,19].  
 
The TRPA1 channel is also expressed in DRG and trigeminal ganglia[14,22] 
and is reportedly activated by cooling temperatures beginning 5-6oC lower than that 
for TRPM8[14,20] and by noxious chemicals such as cinnamaldehyde and mustard 
oil[14,20,21]. However, the role of TRPA1 in physiological cold sensation is currently 
unclear[13] with some reports of TRPA1 not being activated by cold[21,22], and of 
normal cold sensitivity in TRPA1 knockout mice[23]. In contrast, another study of 
TRPA1 knockout mice reported attenuated responses to noxious cold[24], and 
antisense knockdown studies show a decrease in development of nerve injury- or 
inflammation-induced hyperalgesia to intense cold stimuli[25,26]. On balance, TRPA1 
seems a less likely candidate than TRPM8 for the mediator of cooling-induced 
analgesia.  
 
A central spinal mechanism of analgesia is suggested, since cutaneous 
cooling can prevent pain produced by afferent stimulation[4]. Glutamate receptor-
dependent plasticity in spinal cord neurons commonly underlies chronic pain states 
with both ionotropic and metabotropic receptors participating at pre- and post-
synaptic sites. Although most glutamate receptors are excitatory, the Group II/III 
metabotropic receptor (mGluR) subtypes exert inhibitory influences, suggesting the 
hypothesis that they could potentially underpin cooling-induced analgesia. Indeed, 
Group II and III mGluRs are present in spinal cord largely on afferent terminals, but 
with some glial and post-synaptic expression[27,28] and their activation inhibits both 
nerve injury- and inflammation-induced sensitisation of neuronal and behavioural 
responses[29,30,31].  
 
Here we demonstrate marked analgesic effects of peripherally or centrally 
applied TRPM8 activators (such as icilin or menthol), or mild cooling of the skin, in a 
model of neuropathic pain. TRPM8 levels in DRG and superficial dorsal horn were 
increased following nerve injury. Analgesia was restricted to injury-sensitised 
responses and abolished following antisense knockdown of TRPM8. Peripheral 
application of icilin or menthol also activated slowly conducting afferents (in a 
TRPM8-antisense-sensitive manner) and suppressed the increased responsiveness 
of single dorsal horn neurons ipsilateral to nerve injury. In contrast, activation of 
TRPA1 produced hyperalgesia (in both naïve animals and nerve-injured animals). 
TRPM8-mediated analgesia was selectively reversed by intrathecal administration of 
Group II/III mGluR antagonists and mimicked by agonists, while ionophoresis of 
Group III mGluR antagonist, as an example, reversed the inhibitory effect of icilin on 
sensitised single neurons. Sensitisation-specific analgesia from TRPM8 activation 
was also observed in inflammatory, afferent demyelination and TRPA1 activator-
induced pain models.  
 
 
Results  
 
Reversal of nerve injury-induced reflex sensitisation by peripheral activation of 
TRPM8 channels 
 
In order to model potential clinical usage, we administered icilin topically to 
the paws by placing rats with chronic constriction injury (CCI) to sciatic nerve in a 
bath with 1 cm deep drug solution, kept at 30oC to avoid any effects on local skin 
temperature. After 5 min, icilin (80µM), but not vehicle (0.2% dimethylformamide in 
water), caused striking reversal of CCI-induced behavioural reflex sensitisation to 
thermal and mechanical stimuli (Fig 1A). Concentration-dependent effects were 
observed from 2.5µM up to a maximum of 500µM, with no effect on contralateral or 
naïve responses (Fig 1B). At much higher concentrations of icilin, we observed the 
beginning of a trend towards increasing reflex sensitivity, ipsilateral and contralateral 
to CCI and in naives (Table 1), that was statistically significant in mechanical and 
(after a delay) in thermal tests, only at the highest concentration tested, 5 mM. This 
effect was distinct from the prominent analgesia at low concentrations of icilin as it 
was not specific to a sensitised state and may be due to weak interaction with other 
targets or non-specific actions. Specific reversal of sensitised responses was also 
caused by another selective TRPM8 activator, (-)-menthol (4mM). The stereoisomers 
isomenthol and (+)-menthol, which are several fold less potent agonists of 
TRPM8[32,33] also produced reversal of sensitised responses at concentrations of 
8mM and 16mM (Fig 1C).  
 
Icilin is expected to activate TRPM8-containing afferents, so we recorded 
firing activity in saphenous nerve afferents following topical application of icilin (Fig 
1D). The nerve was dissected to produce small-number preparations of fine 
afferents, with conduction velocities of up to 2.6ms-1 (representing C- and Aδ-fibre 
afferents[34]). Icilin (200µM) applied to the receptive field on the hindlimb caused a 
significant increase in firing frequency in 21.6%  (40 out of 185) of recorded fine 
afferents with a mean 7-fold increase in firing frequency from baseline of 4.5 ± 2.5 Hz 
to 31.6 ± 3.4 Hz, mean time to peak effect of 3.3 ± 0.5 mins. Icilin did not produce 
rapid desensitisation, agreeing with some[35], but not other reports[36]. Recovery was 
consistently observed. Similar results were obtained from both hairy and glabrous 
skin. Large myelinated mechanoreceptors (conduction velocities 6.8-15ms-1, n=43) 
were unaffected.  
 
Consistent with a TRPM8-mediated mechanism, paw immersion at 16-20oC 
for 5 min also produced statistically significant mechanical analgesia (Fig 1E). 
Recordings from a subcutaneous thermistor probe showed that deep skin 
temperatures were 0.5oC above bath temperatures after 5 min in similar conditions. 
This temperature is in the range expected to activate TRPM8, and stimulate 
innocuous cool-sensitive fibres. Immersion temperatures below 14oC (in the range 
where other cold sensors, in addition to TRPM8, are also likely to be activated) 
elicited active nociceptive withdrawal reflexes limited to the period of hindpaw 
immersion, in agreement with the known temperature activation range for nociceptive 
cold fibres[37]. 
 
Localisation of TRPM8 in afferents and superficial dorsal horn: increased 
expression following nerve injury 
 
The presence and localisation of TRPM8 in DRG and spinal cord were 
investigated by immunoblotting and immunohistochemistry. Following rapid 
homogenisation of DRGs in Laemmli lysis buffer and SDS-PAGE, immunoblots 
probed with a rabbit polyclonal antibody raised to TRPM8 residues 278-292 and 
1090-1104 (human)[38], showed a single, strong band at approximately 128 kDa (the 
predicted molecular weight of TRPM8), with faint bands observed at approximately 
170, 60 and 50 kDa (Fig 2A). Both antigen-preabsorbtion and antisense-knockdown 
controls were consistent with specificity of this antibody in recognition of TRPM8 at 
approximately 128 kDa under the conditions used. Pre-incubation of the antibody 
with membranes from COS7 cells transfected with TRPM8 expression plasmid 
abolished the band at 128kDa, whereas sham preabsorbtion with membranes from 
cells with empty vector did not (Fig 2A). Correspondingly, intrathecal delivery of 
TRPM8 antisense oligonucleotide to naïve (non-CCI) rats over 5 days, also resulted 
in almost complete knockdown of the 128kDa band (Fig 2A), whereas mis-sense 
control oligonucleotide was ineffective (see below). Intrathecally delivered 
fluorescent-labelled oligonucleotides have been shown to effectively penetrate the 
DRG, as soon as 4 hours after initial delivery[39]. The faint bands, at 50 and 60 kDa at 
least, remained present in each case and so are likely to represent non-specific 
interactions of the antibody under these conditions. As further controls, we showed 
that TRPV1 immunoreactivity was unaffected by treatment with the TRPM8 antisense 
reagent and that the housekeeping enzyme GAPDH (36kDa) was evenly present in 
each lane (Fig 2A). Following nerve injury, there was a marked increase in 
expression of the 128kDa TRPM8-immunoreactive band specifically in ipsilateral, but 
not contralateral DRG (Fig 2A), while immunoreactivity for GAPDH was unaltered. 
Densitometric ratios for TRPM8 expression as percentage of GAPDH were 80.7 ± 
4.1 ipsilateral to CCI, which was significantly greater than that seen contralateral to 
CCI (49.3 ± 3.2) and in naïve DRG (50.7 ± 2.7), (means ± SEM, n=5-6). L4-5 spinal 
cord extracts showed that TRPM8 immunoreactivity was present centrally, and after 
preparation of a crude particulate fraction (centrifugation at 11,000g for 45 min) these 
also showed consistent increases in expression ipsilateral to injury. Densitometric 
values ipsilateral to CCI were 198 ± 6.7% of those in naives (p<0.05; means ± SEM, 
n=5), whereas contralateral values were 125 ± 7.1% (p>0.05).  
 
Immunohistochemistry was carried out using a rabbit polyclonal antibody 
raised to TRPM8 residues 656-680 (rat)[40], the specificity of which was addressed by 
antigen preabsorbtion and antisense knockdown controls. The labelling observed in a 
discrete subpopulation of DRG cells was abolished following pre-incubation with the 
peptide antigen (no positive cells seen, counted over twelve 500µm2 sections, 
compared with a mean of 5.3 ± 0.4 TRPM8-positive cells per 500 µm2 DRG section 
with sham treatment of antibody, and 5.1 ± 0.5 TRPM8-positive cells per 500 µm2 
DRG section with untreated antibody, counted over 12 sections each). In 
immunoblots, the antibody also labelled a single band at approximately 128kDa in 
naïve DRG tissue that was abolished either by preabsorbtion with the peptide antigen 
or by prior 5 day intrathecal infusion of TRPM8 antisense (Fig 2B). 
Immunohistochemical staining in spinal cord showed that TRPM8 in spinal cord was 
largely expressed in superficial dorsal horn, like the C-fibre marker, peripherin (Fig 
2C) and that following dorsal rhizotomy (L2-6), the vast majority of TRPM8 (and 
peripherin) immunoreactivity was lost ipsilaterally (reductions of approximately 80-
90%) suggesting that spinal TRPM8 originates largely from afferents. In confirmation 
of the immunoblot findings, levels of TRPM8-like immunoreactivity were increased in 
dorsal horn ipsilateral to injury (by approximately 70-80%), but retained a similar 
distribution to that in naïve animals (Fig 2D).  
 
To establish whether the increases in afferent TRPM8 expression occurred in 
specific subpopulations of DRG cells, we investigated TRPM8 colocalisation with 
markers of myelinated afferents (neurofilament-200; NF-200[41]) and unmyelinated 
afferents (peripherin[42]). In naïve rats, TRPM8 immunoreactivity was largely confined 
to a subpopulation of unmyelinated DRG cells (8.3 ± 0.2% of peripherin-positive 
cells; 34 of 408 cells) and only minimally expressed in myelinated, NF-200-positive 
cells (1.3 ± 0.5%; 6 of 445 cells). However, following CCI, TRPM8 expression was 
significantly increased ipsilaterally in both NF-200- and peripherin-positive cells to 7.9 
± 1.2% (31 of 390 cells) and 15.5 ± 0.8% (64 of 412 cells), respectively. 
Corresponding contralateral values were unaltered from naives at 2.0 ± 0.4% (14 of 
346 cells) and 9.2 ± 0.4% (42 of 452 cells) (Fig 2 E, F). Data taken from 3 CCI and 3 
naïve animals, counted across 15 - 21 sections. The additional TRPM8-expressing 
NF-200-positive cells were small (average diameter, 19.7 ± 0.8µm), presumed Aδ 
myelinated neurons[34]. There were no significant differences in the diameters of NF-
200- or peripherin-positive cells or in the numbers of NF-200- or peripherin-positive 
DRG neurons per section.  
 
Molecular identification of TRPM8 as the mediator of icilin-induced analgesia 
  
To define the specific involvement of TRPM8 in icilin analgesia we further utilised the 
antisense oligonucleotide knockdown strategy. TRPM8 antisense or mismatched 
control oligonucleotides were delivered intrathecally over 13 days to parallel the 
sensitisation developing following CCI. The development of CCI-induced behavioural 
reflex sensitisation was unaffected, including thermal hyperalgesia and mechanical 
allodynia (Fig 3A, B) and cold allodynia (control CCI animals showed elevation of the 
paw ipsilateral to nerve injury out of 4oC water for 8.1 ± 0.5 s at peak, 9-11 days after 
surgery, whereas corresponding values in antisense-treated CCI animals were 7.6 ± 
0.6s). In contrast, the reversal of neuropathic reflex sensitisation produced normally 
by 80µM icilin applied to the paws (Fig 1A) was abolished by treatment with 
antisense (Fig 3A), but not mis-sense (Fig 3B) reagents. The mean ± SEM % 
reversals of ipsilateral sensitisation over 10-25 minutes after icilin treatment in 
antisense- and mis-sense-treated animals were 7.7 ± 7.4% and 82.8 ± 6.9%, 
respectively for PWL, and 9.4 ± 8.2% and 58.7 ± 8.2% for PWT; with mis-sense-
treated, but not antisense-treated animals, retaining significant effects of icilin 
(p<0.05).  When antisense osmotic pumps were depleted, but animals were still 
neuropathic (18 days following surgery for insertion of 14 day minipumps and CCI), 
responses to icilin were restored to 83.7 ± 10.1% reversal of sensitisation for PWL, 
and 54.0 ± 7.2% for PWT. Effectiveness of knockdown was assessed by SDS-
PAGE/immunoblotting. Expression of the 128kDa TRPM8-immunoreactive band in 
both ipsilateral and contralateral DRGs was greatly reduced by the antisense reagent 
and the increase in TRPM8 expression normally seen ipsilateral to nerve injury was 
prevented (Fig 3C). The mis-sense reagent had no effect (Fig 3C) showing TRPM8 
expression similar to that in untreated CCI animals (Fig 2A). In mis-sense-treated 
animals, TRPM8:GAPDH ratios were 77.9 ± 2.0% ipsilateral to CCI and 52.9 ± 2.1% 
contralateral, similar to corresponding control values (Fig 2A and above), whereas in 
antisense-treated animals, values were much lower (19.8 ± 2.2% and 14.9 ± 2.1%, 
respectively, means ± SEM, n=5).  
 
To confirm that antisense knockdown of TRPM8 resulted in associated 
functional changes in afferents, saphenous nerve recordings were made from naïve 
animals receiving intrathecal delivery of TRPM8 antisense or mis-sense 
oligonucleotides, 4-5 days after insertion of pump. The increase in firing frequency 
evoked by topical icilin (200µM) was strongly reduced in animals receiving antisense. 
Only 3 out of 34 recorded slowly conducting fibres (8.8%) showed a partial activation 
in response to drug, increasing firing by approximately 2-fold from a baseline of 5.8 ± 
1.4 to 12.7 ± 0.6 Hz, compared with the 7-fold increase observed in over 20% of fine 
afferents in naïve animals. In contrast, mis-sense animals showed a 7-fold increase 
in firing frequency in 25% of 40 recorded fibres from a baseline of 3.3 ± 0.7 to 23.1 ± 
3.2 Hz, similar to results from naïve animals. Similarly, in mis-sense-treated animals, 
topical (-)-menthol (4mM) produced an approximately 8-fold increase in mean firing 
frequency (from 4.5 ± 2.9 to 38.9 ± 7.6Hz), activating 20% of fibres (35 identified 
afferents recorded). This compared with no obviously activated afferents in 
antisense-treated animals (mean firing frequency 4.0 ± 1.8Hz at background, 4.8 ± 
1.9 Hz post-drug application, 28 identified afferents recorded). However, TRPM8 
antisense treatment did not alter the effect of topically applied resiniferatoxin (1mM), 
a potent TRPV1 agonist, acting as a control. In antisense-treated animals, 
resiniferatoxin evoked a 6-fold increase in firing frequency in activated afferents (from 
4.5 ± 0.7 baseline to 25.9 ± 1.8 Hz at peak response, 16 afferents activated out of 28 
recorded), which was similar to responses in mis-sense-treated animals (showing a 
mean 5-fold change in firing frequency from 4.6 ± 2.8 to 24.8 ± 3.1Hz).  
 
Central intrathecal administration of TRPM8 activators also inhibits 
neuropathic sensitisation  
 
Since TRPM8 is present on central terminals of primary sensory neurons as 
well as their peripheral terminals (Fig 2B,C,[43,44]), we investigated whether intrathecal 
application of TRPM8 activators near to the central terminals would also produce 
analgesia. Intrathecal injection of icilin (10nmol) produced robust reversal of CCI-
induced behavioural reflex sensitisation in thermal and mechanical tests (Fig 4A, 
p<0.05 for up to 55 min). Intrathecal injection of (-)-menthol (200nmol) in CCI rats 
also caused a significant reversal of the sensitised responses, lasting 35-40 min (Fig 
4B). Due to the higher potency and efficacy of icilin at TRPM8[15], further experiments 
mainly utilised icilin as the representative TRPM8 activator. Icilin produced dose-
dependent analgesic effects restricted to the nerve injury side in both thermal and 
mechanical tests that were statistically significant by 0.125nmol and increased to 
almost complete reversal of sensitisation by 10nmol. Non-linear curve-fitting 
indicated that maximal effects of icilin were similar for PWL and PWT (91.6 ± 9.9 and 
82.6 ± 6.8% reversal of sensitisation, respectively), as were EC50 values (dose for 
50% of maximal effect; 0.17 ± 0.02 and 0.31 ± 0.02 nmol, respectively).  
 
In complete contrast to the effects of TRPM8 activators, the TRPA1 activator, 
cinnamaldehyde[20] (75nmol injected intrathecally) significantly increased reflex 
responsiveness in thermal and mechanical tests and was effective contralateral as 
well as ipsilateral to nerve injury (Fig 4C). The sensitising effects of cinnamaldehyde 
were prevented by co-injection of Ruthenium Red (0.25nmol), which can block 
TRPA1 channels[22,46], whereas the analgesic effect of intrathecally-injected icilin was 
unaffected (Fig 4D). Sensitising effects of cinnamaldehyde were also seen in naïve 
animals with a 36.9 ± 7.9% reduction in PWL and a 41.9 ± 6.7% reduction in PWT. 
Similar effects were produced by two further TRPA1 activators[46,47], allicin (25nmol), 
where corresponding reductions were 33.2 ± 5.9% and 20.7 ± 8.2%, respectively and 
diallyl disulphide (50nmol) with equivalent values of 25.9 ± 7.0% and 28.5 ± 6.2% 
(means ± SEM, n=3-6). In contrast, the TRPM8 activators, icilin (10nmol) and (-)-
menthol (200nmol) were without effect in naïve animals (data not shown). Topical 
application of cinnamaldehyde (1.5mM) also produced bilateral sensitisation of 
behavioural reflexes in naive animals (mean decrease of 32.0 ± 8.6% in PWL and 
20.2 ± 8.2% in PWT, p<0.05, n=6). This corresponds to the licking and shaking 
behaviour as well as decrease in PWL reported following intraplantar injection of 
cinnamaldehyde[20].  
 
In further experiments, we investigated whether the sensitised pain 
behaviours caused by TRPA1 activators or other pain models were susceptible to 
icilin-induced analgesia. Sensitisation caused by intrathecal or topical 
cinnamaldehyde was markedly attenuated by intrathecal icilin (Table 2). The effect of 
topical cinnamaldehyde was additionally reversed by topical icilin (200µM, data not 
shown). Sensitisation caused by focal demyelination of the sciatic nerve[42] or 
intraplantar injection of Complete Freund’s Adjuvant (CFA) was also significantly 
inhibited by intrathecal icilin (Table 2).  
 
Central mechanism of icilin reversal of neuropathic sensitisation involves 
mGlu group II/III receptors  
 
Since topical icilin increases activity in fine afferents (Fig 1D) and both 
intrathecal and topical icilin reverse nerve injury-induced sensitisation, centrally-
mediated events are likely to be important in icilin action. Icilin-responsive afferents 
are expected to release glutamate, so we hypothesised that inhibitory glutamate 
receptors in dorsal horn might underlie icilin-induced analgesia. Group II/III mGluRs 
could subserve such a role since they are antinociceptive in models of inflammatory, 
neuropathic and acute pain[29,30,31] and inhibit transmission between primary afferent 
and spinal cord neurons in sensitised states[48,49]. Group II mGluRs are localised on 
primary afferent terminals in lamina II, particularly in small nociceptive afferents[27,51], 
although some are found post-synaptically and on glia[28]. Group III mGluRs are also 
found pre-synaptically in the dorsal horn and are 45% co-expressed with either IB4 or 
Substance P (markers of small nociceptive neurons[50]). To assess whether activation 
of Group II/III mGluRs might mimic icilin reversal of neuropathic sensitisation, we 
intrathecally injected the selective Group II or III mGluR agonists, 2R, 4R-APDC or 
ACPT-III and AP-4, respectively. 2R, 4R-APDC (15nmol) caused 72.1 ± 6.4% 
reversal of thermal and 56.0 ± 10.9% reversal of mechanical reflex sensitisation 
ipsilateral to CCI (15-30 min post-injection) with no effect on contralateral responses. 
ACPT-III and AP-4 (150nmol each) also reversed thermal sensitisation (by 83.6 ± 
6.3% and 60.8 ± 6.7%, respectively), as well as mechanical sensitisation (65.7 ± 
11.4% and 60.7 ± 8.0%), again with no effects contralaterally (p<0.05 in each case). 
Furthermore, selective Group II and Group III mGluR antagonists, LY 341495 (5nmol, 
Fig 5A) and UBP 1112 (10nmol, Fig 5B) each prevented the effect of icilin (10nmol, 
Fig 4A). Similarly, the analgesia produced by intrathecal (-)-menthol (200nmol, Figure 
4B) was reversed by intrathecal LY 341495 and UBP 1112. The mean percentage 
reversal of sensitisation over 20-30 minutes post-injection was 86.1 ± 8.1% for PWL 
and 80.6 ± 4.2% for PWT with (-)-menthol alone, 22.0 ± 6.9% for PWL and 7.1 ± 
7.1% for PWT with menthol and LY 341495, and 9.2 ± 6.9% for PWL and 0.0 ± 0.0% 
for PWT with (-)-menthol and UBP 1112 (n=6).  Neither LY 341495 nor UBP 1112 
had any effects alone (data not shown), suggesting that Group II/III mGluRs show 
little tonic activation following CCI, but are specifically utilised downstream of icilin. In 
contrast, intrathecal co-administration of the µ-opioid receptor antagonist, naloxone 
(25nmol) with icilin had no effect (Fig 5C), indicating that icilin analgesia is opioid-
independent. To avoid any possibility of non-specific drug interactions, we also 
administered icilin (200µM) topically, but the mGluR antagonists, intrathecally. Fig 5D 
shows that the icilin reversal of thermal and mechanical sensitisation in this case was 
again prevented by LY 341495 or UBP 1112. The analgesic effect of skin cooling to 
16 oC (Fig 1E) was also prevented by intrathecally applied LY 341495 (5 nmol) or 
UBP 1112 (10 nmol). The mean percentage reversal of ipsilateral CCI-induced 
reductions in PWT caused by cooling was 0.0 ± 0.0% in the presence of either drug 
(n=5).  
 
To confirm the analgesic effect of icilin at the level of single spinal cord 
neurons, we made in vivo extracellular recordings of large lamina I and III/IV neurons 
(that integrate nociceptive and non-nociceptive inputs). Topical administration of icilin 
(200µM) to the peripheral receptive field area ipsilateral to CCI caused inhibition of 
the elevated neuronal responses to motorised rotating brush (Fig 5E). In the 8 
neurons out of 12 that were affected by icilin (2 in lamina I and 6 in laminae III/IV) 
brush-induced responses were reduced to 37.4 ± 5.5%, p<0.001). Vehicle had no 
effect. Contralateral neurons were unaffected (111.9 ± 8.9% of control; n=6). As an 
example of one of the Group II/III mGluR antagonists investigated on reflexes, UBP 
1112 was ionophoresed in the vicinity of recorded dorsal horn neurons at currents of 
20-60nA. UBP 1112 reversed the effect of icilin; the brush-induced firing rate reverted 
to 80.2 ± 9.3% of control values (Fig 5E), but UBP 1112 had no effect alone, nor did 
saline current controls.  
 
Since some Group II/III mGluRs may be post-synaptic, we asked whether 
icilin could reverse the additional sensitisation of behavioural reflex responsiveness 
caused by intrathecally applied NMDA in CCI animals. Icilin (10 nmol) clearly 
attenuated the additional ipsilateral sensitisation induced by 3.75 nmol of NMDA plus 
0.75 nmol of its co-agonist site activator, ACPC, injected intrathecally. Ipsilateral 
PWL values in thermal tests were 10.1 ± 0.6 s at baseline and decreased to 7.9 ± 
0.3s (15-30 minutes after injection of NMDA/ACPC), but increased to 14.9 ± 0.6 s in 
the additional presence of icilin. Contralateral values were unaltered by icilin or 
NMDA/ACPC. Ipsilateral PWT values in mechanical tests were 1504.2 ± 105.3 
mN/mm2 at baseline, 891.6 ± 27.3 mN/mm2 after injection of NMDA/ACPC and 
3482.7 ± 174.3 mN/mm2 with co-injection of icilin (means ± SEM, n=6). Contralateral 
values again were unaltered. A component of the central events elicited by icilin may 
therefore be post-synaptic, although it is important to note that functional NMDA 
receptors may also be present on afferent terminals[52]. 
 
Discussion 
 
Little is known of the mechanism underlying cooling-induced analgesia, but a 
number of cool-sensitive ion channels, including TRPM8, have recently been 
identified in somatosensory afferents[13]. We now show that TRPM8 activation 
reverses nerve injury-induced hypersensitivity. TRPM8 can be activated by 
menthol[15,16], which is analgesic in hot plate and acetic acid writhing tests[11], 
although menthol can produce pain at very high doses[53,54]. Here, either topical or 
intrathecal application of (-)-menthol produced behavioural analgesia in the CCI 
model of neuropathic pain, most likely by activation of TRPM8. Similar effects were 
seen with another TRPM8 activator, icilin[15]. As with menthol, very high doses of icilin 
were found to cause a generalised increase in sensitisation, affecting CCI animals 
bilaterally and naïve animals in a similar fashion (Table 1). Importantly, analgesic 
effects of icilin were seen at 200-fold lower concentrations than those causing non-
specific sensory changes. Specific involvement of TRPM8 in the reversal of 
neuropathic sensitisation was confirmed by the abrogation of icilin analgesia 
following intrathecal infusion of a TRPM8 antisense oligonucleotide to knock-down 
TRPM8 expression. Furthermore, the analgesic profile was mimicked by cutaneous 
cooling to 20-16oC, a range activating the TRPM8 channel[14].  Icilin and menthol 
were applied cutaneously in solution at 30oC, so any possible drug effects on skin 
temperature were avoided. TRPM8 antisense had no effect alone on CCI-induced 
sensitised responses to noxious heat, mechanical stimuli or intense cold (Fig 3), 
similar to observations made in an alternative neuropathic pain model[26]. A role for 
the TRPA1 channel in analgesia seems unlikely since selective TRPA1 activators, 
cinnamaldehyde, allicin and diallyl disulphide, caused contrasting 
sensitisation/hyperalgesia not only after CCI, but also in naïve animals. The 
analgesic effects of icilin were only seen in the sensitised pain state, but were not 
restricted to nerve injury, since sensitisation due to peripheral inflammation, afferent 
demyelination and TRPA1 activation was also reduced. The significant behavioural 
and electrophysiological effects of topically applied icilin demonstrate that icilin can 
cross the skin sufficiently to excite peripheral afferents, and point to the likely clinical 
utility of this or related drugs. 
 
The precise identity of the TRPM8-containing cool-responsive afferents is not 
clear. Subpopulations of Aδ- and C-fibres are responsive to different ranges of cool 
temperatures ~15-30oC, and <15oC[55,37]. Innocuous cooling (15-30oC) activates a 
subpopulation of Aδ- and C-fibres in primates, but almost solely unmyelinated fibres 
in rodents[55]. In contrast, intense noxious cold is signalled by unmyelinated 
polymodal nociceptors, which also respond to heat and mechanical stimuli[37]. The 
TRPM8 activator menthol activates cool-sensitive fibres, and sensitises stimulus-
induced responses in the range 20-30 oC[56,57]. Studies of TRPM8 in vitro identify this 
channel as a likely transducer of moderate cool temperatures[19]. In DRG and 
trigeminal cultures, responses to menthol, cooling (15-30oC) and TRPM8 mRNA 
expression all correlate closely[17,18,19]. TRPM8 is expressed in 5-20% of DRG cell 
bodies that are small and presumed Aδ- or C-fibres[15,16], but not in large myelinated 
fibres. We observed that TRPM8 immunoreactivity is normally associated with a 
subpopulation of peripherin-positive C-fibres, but only minimally with NF-200-positive 
afferents, whereas high sensitivity cRNA hybridisation suggests the presence of 
some TRPM8 mRNA in up to 19% of NF-200-positive afferents[58]. The capsaicin- 
and heat-sensitive TRPV1 channel, which contributes to thermal nociception and 
inflammatory sensitisation[12], is found in both peptidergic afferents (~85%), and non-
peptidergic (isolectin-B4, IB4-positive) cells in the rat[59]. TRPM8 is not categorically 
associated with either peptidergic or IB4-positive afferents[15] but is often present in 
those containing the NGF receptor, Trk A[58]. Different groups have reported co-
expression of mRNAs for TRPM8 and TRPV1 or menthol/capsaicin responsiveness 
of DRGs at 29-50%[15,19,60] or close to zero[14,16,58]. Overall it seems likely that TRPM8 
is normally expressed in a distinct population of cool-responsive afferents and 
possibly also to an extent in some nociceptors. Our findings further identified 
increased expression in peripherin-positive C-fibres, but induction in small NF-200-
positive presumed Aδ-fibres[34], suggesting that plasticity in TRPM8 expression may 
participate in icilin analgesia in neuropathic pain. No changes in DRG expression of 
TRPM8 were reported in an alternative neuropathic pain model (ligation of L5 spinal 
nerve or indeed following CFA) [25,26], suggesting that specific aspects of the particular 
model, such as the co-existence of injured and uninjured afferents in DRG following 
CCI, may be important in TRPM8 upregulation.  
 
TRPA1, which has also been proposed as a cool receptor[14] appears to play 
an entirely different role, eliciting reflex pain behaviours in naïve animals, as well as 
increasing thermal and mechanical responsiveness in the neuropathic state. This 
may correspond to clinical observations after nerve injury in which moderately cool 
stimuli are perceived as painful[1]. TRPA1 is present mainly in small cells in sensory 
ganglia[14,22] and may increase ipsilateral to nerve injury and inflammation[25,26]. Nerve-
injury and inflammation-induced hyperalgesia to noxious cold (5oC) is reported to be 
decreased by antisense knockdown of TRPA1[25,26]. Correspondingly, mutant mice 
homozygous for targeted disruption of the TRPA1 gene show reduced reflex 
withdrawal responses to selective TRPA1 activators and reduced sensitisation of 
noxious heat and innocuous mechanical responses caused by these agents[23]. 
However, the role of TRPA1 in noxious cold responses is disputed, with results from 
different lines of TRPA1-/- animals showing either attenuated or unaltered coldplate 
withdrawal responses[23,24]. Thus the precise role of TRPA1 in cold sensation remains 
unclear, but here as in other studies TRPA1 clearly acts in a pro-nociceptive 
manner[20,23,46,47]. Although icilin may interact with low potency at the TRPA1 
channel[14], the analgesic profile of TRPM8 activators here is entirely different from 
the pro-nociceptive profile of TRPA1 activators. The extent of TRPM8/TRPA1 co-
expression in afferents is reported to be minimal[14,58].  
 
The analgesia induced by icilin and menthol and by skin cooling to 16oC was 
shown to be centrally-mediated and dependent on Group II/III mGluRs. The lack of 
effect of naloxone suggests independence from classical opioid analgesia. 
Furthermore, at the doses used, mGluR Group II/III antagonists selectively reversed 
icilin and menthol analgesia in sensitised responses, without any effects alone. 
Group II/III mGluRs are known to inhibit nociceptive responses[29,30,31,48,49] and we 
showed that Group II/III mGluR agonists selectively inhibit sensitised responses in 
neuropathic pain. Both Group II and III mGluR subtypes are expressed in primary 
afferents, especially IB4-positive cells[27,50,51]. Activation of Group II/III mGluRs can 
inhibit afferent-evoked potentials in dorsal horn[48], since Group II mGluRs are both 
pre- and post-synaptic at primary afferent synapses[28], whereas Group III mGluRs 
are largely pre-synaptic[50]. Menthol is reported to increase mEPSC frequency at 
some synapses between DRG and dorsal horn neurons in culture and in slices[43,44], 
presumably corresponding to the activation of TRPM8-containing afferents (Fig 1D) 
and increased release of glutamate. Figure 6 shows a schematic outline of a model 
in which glutamate released from TRPM8-expressing afferents could mediate icilin-
induced analgesia by acting on Group II/III mGluRs (located pre-synaptically on 
nociceptive afferents and possibly also post-synaptically) to result in attenuation of 
pain-related sensitisation (Fig 5E) and behavioural analgesia (Fig 5D).  
 
Conclusions 
 
In summary, these novel findings show that both peripheral and central 
activation of TRPM8 can produce an analgesic effect that specifically reverses the 
sensitisation of behavioural reflexes elicited by peripheral nerve injury. This effect is 
produced by very low concentrations of topically applied TRPM8 activators, pointing 
to the likelihood of its ready utility in a clinical context. Other sensitised pain states, in 
addition to that induced by nerve injury, are similarly sensitive to reversal by TRPM8 
activation, emphasising the likely value of TRPM8 activators and downstream central 
mediators of TRPM8 action, such as Group II/III mGluRs, as targets for the 
development of novel analgesics. 
 
 
Experimental Procedures 
 
Animals 
All experiments were conducted in accordance with the UK Animals (Scientific 
Procedures) Act, 1986, and guidelines of the University of Edinburgh. Adult male 
Wistar rats (Harlan, UK) weighing between 120-250g were used for all experiments. 
 
Neuropathic and inflammatory pain models  
Pain models were generated under halothane anaesthesia (Zeneca, Cheshire, UK). 
For the chronic constriction injury (CCI) model of neuropathic pain, four ligatures 
were tied loosely to constrict the sciatic nerve at mid-thigh level (as described 
previously[61]). An inflammatory pain model was generated by injecting 100µl of 
Complete Freund’s Adjuvant (CFA, Sigma-Aldrich Ltd) into the ventral surface of the 
right hindpaw[61]. A model of peripheral demyelination-induced pain was produced by 
focal application of lysolecithin to the sciatic nerve[42]. Peak behavioural sensitisation 
was observed post-surgically between days 10-16 for CCI, 1-3 for CFA, and 7-14 for 
lysolecithin, when pharmacological and electrophysiological experiments and tissue 
removal were conducted. 
 
Behavioural testing 
Thermal sensitivity was assessed by measuring paw withdrawal latency (PWL, s) in 
response to a noxious thermal stimulus (Hargreaves’ thermal stimulator, Linton 
Instrumentation, Diss, UK) directed to the hindpaw mid-plantar glabrous surface. 
Mechanical sensitivity was recorded as the paw withdrawal threshold (PWT, 
mN/mm2) to calibrated von Frey filaments (Stoelting, Illinois, US), as previously 
described[61]. Sensitivity to noxious cold was assessed by placing animals in a 
waterbath with an aluminium floor containing 1cm deep 4oC water and counting the 
time the paw was held suspended over a 20 s period.   
 
Intrathecal application of drugs  
The following drugs were applied intrathecally in a 50 µl volume of saline-based 
vehicle at 37oC: icilin (2.5-200 µM in saline with 0.2% dimethylformamide, DMF), LY 
341495 (100 µM in saline), UBP 1112 (200 µM in saline), 2R, 4R-APDC ((2R, 4R)-4-
aminopyrrolidine-2,4-dicarboxylate), 300 µM in saline), ACPT-III ((1R,3R,4S)-1-
aminocyclopentane-1,3,4-tricarboxylic acid), 3 mM in saline), AP-4, ((L-(1)-2-amino-
4-phophonobutyric acid), 3 mM in saline), naloxone (0.5 mM in saline), NMDA (75 
µM in saline) and ACPC (1-aminocyclopropanecarboxylic acid, 15 µM in saline)  
(Tocris Cookson, Bristol, UK), (-)-menthol (1R, 2S, 5R-(-)-menthol, 4 mM in saline), 
cinnamaldehyde (1.5 mM in saline) and Ruthenium Red (5 µM in saline) (Sigma-
Aldrich Co. Ltd, UK) and allicin (0.5 mM in saline with 0.5% DMF) and diallyl 
disulphide (DADS, 1 mM in saline with 0.5% DMF) (LKT Laboratories Inc., St Paul, 
MN, USA). Drugs were injected into the L5/6 intrathecal space under brief halothane 
anaesthesia, using a 25-gauge needle microsyringe (BD Biosciences, Oxford, UK), 
as described previously[61] in animals that were at peak levels of behavioural 
sensitisation. Behavioural reflex testing commenced 15 min following injection to 
allow recovery from anaesthesia[42,62,63] and continued every 5 min thereafter until 
readings returned to baseline levels (n = 6 in each case). We, and others[42,62,63] find 
complete recovery from anaesthetic by 15 minutes. All appropriate controls were 
carried out to eliminate the possibility of effects due to vehicle or to injection 
procedure. 
 
The TRPM8 channel activators, icilin and (-)-menthol were tested in CCI and naïve 
animals. The effects of icilin were additionally assessed in animals with CFA-induced 
inflammation or with lysolecithin-induced demyelination. Icilin was also co-
administered with the µ-opioid receptor antagonist naloxone, the Group II 
metabotropic glutamate receptor (mGluR) antagonist, LY 341495, or the Group III 
mGluR antagonist, UBP 1112. The effects of these antagonists alone as well as 
effects of the Group II mGluR agonist, 2R, 4R-APDC and the Group III mGluR 
agonists, ACPT-III and AP-4, were assessed in CCI animals. The TRPA1 channel 
activator, cinnamaldehyde, alone and with icilin, was tested in CCI animals and in 
naïve animals. Further TRPA1 channel activators, allicin and diallyl disulphide were 
assessed in naïve animals.  Both icilin and cinnamaldehyde effects in CCI animals 
were also investigated in the additional presence of Ruthenium Red.  
 
Topical application of drugs 
Icilin was applied at concentrations of 2.5–500 µM (in water with 0.2% DMF), by 
placing CCI or naïve rats unrestrained for 5 min in a 1 cm deep waterbath (sufficient 
to cover paws), which was thermostatically controlled to a temperature of 30oC, or by 
very lightly anaesthetising rats and immersing hindpaws in small tubes containing 5 
ml icilin (500 µM–5mM, with a vehicle of 45% dimethylformamide in 0.2% aqueous 
Tween 80) for 5 min, followed by sensory testing for 60-80 mins. The effects of (-)-
menthol and its stereoisomers isomenthol (1S, 2R, 5R-menthol,) and (+)-menthol 
(1S, 2R, 5S (+)-menthol) (4 – 16mM in 80% ethanol) were also assessed. Relevant 
vehicles were always assessed in similar experiments. As a contrast, the effect of 
cinnamaldehyde (1.5mM in water) and the effect of cinnamaldehyde with additional 
icilin (80 µM in water with 0.2% DMF) were assessed in naïve animals. The effects of 
icilin (80 µM) were further assessed in CCI animals that had undergone antisense 
and mis-sense treatment for knockdown of TRPM8 or immediately following 
intrathecal injection of either LY 341495 or UBP 1112. Actual skin temperatures were 
measured by subcutaneous thermistor probe and were found to equilibrate to around 
0.5oC above bath temperature. The effects of brief paw immersion at different 
temperatures (10-22oC for 5 min) on CCI rats were assessed by mechanical testing. 
The effects of intrathecal LY 341495 or UBP 1112 on the reversal of ipsilateral 
sensitisation in CCI following a 16oC cool challenge for 5 min were measured. Reflex 
testing commenced 5 minutes following challenge, unless animals had been 
anaesthetised, in which case 15 minutes was allowed for recovery. Six replicate 
animals were tested in all pharmacological experiments. 
 
Dorsal rhizotomy  
To establish whether TRPM8 expression in spinal cord was predominantly pre- or 
post-synaptic, a unilateral L2-6 dorsal rhizotomy was performed under anaesthesia, 
following laminectomy to expose the dorsal roots. Eight days later, tissue was 
removed and processed for immunohistochemistry.  
 
Western blots 
Experiments were performed by standard procedures as previously described[61], for 
more detail see Supplementary material.  
 
Immunohistochemistry 
Experiments were performed as previously described[42], for more detail see 
Supplementary material.  
 
Antisense knockdown of TRPM8 
Antisense and mis-sense oligonucleotides were 22-mers with phosphorothioate 
bonds at the last two positions at 5’ and 3’ ends (MWG Biotech, Ebersberg, 
Germany). Antisense extended from base –10 to base +12 relative to the start of the 
open reading frame for the rat TRPM8 gene: 5’ 
C*T*CGAAGGACATCTTGCCGT*G*G 3’, where * represents phosphorothioate 
linkages. Mis-sense was designed with 4 inversions of C/G or A/T as appropriate at 
residues 3, 11, 14 and 22, preserving overall G/C content. BLAST searches of both 
oligonucleotides indicated no significant complementarity to any known gene 
sequence. 14-day or 7-day osmotic minipumps (for CCI experiments or naïve 
electrophysiology experiments respectively - Alzet Minipump, models 2002, 2001; 
Charles River, UK) containing oligonucleotides (1µg/µl in sterile saline) were 
connected to canulae inserted under the dura of the spinal cord to level L5/6 and 
produced a predicted infusion rate of 0.5 µl/h. CCI surgery was performed at the 
same time as minipump implantation. Sensory tests were carried out to assess the 
time-course of behavioural sensitisation in animals which had also undergone a CCI 
injury. Icilin was applied topically rather than intrathecally so as to prevent any 
interference with the infusion canula. Peripheral nerve recordings and tissue 
harvesting were carried out after an interval of 4-5 days to allow time for protein 
knockdown. 
 
Electrophysiology 
Peripheral: Recordings of saphenous (sensory) nerve were made in naïve animals 
(n=7) to assess the effects of topical icilin on primary afferents. In addition, 
recordings were carried out on animals which had undergone TRPM8 antisense or 
mis-sense treatment beginning 4-5 days previously. Rats were anaesthetised (with 
0.6ml 25% urethane /100g, i.p.) and the saphenous nerve was exposed and 
dissected from its associated vein and artery. Further dissection under liquid paraffin 
enabled identification of afferent preparations comprising a small number of fibres. 
The conduction velocity of single identified afferent fibres was determined using 
bipolar electrodes and the peripheral stimulus technique[64]. Following isolation of 
preparations, icilin (200µM in water with 0.2% DMF), (-)-menthol (4mM in 25% 
ethanol) resiniferatoxin (1mM in ethanol) or vehicle alone were applied to the 
hindlimb receptive fields and neuronal responses recorded using the Chart 
programme (version 3.6).  
 
Central: Recordings of spinal dorsal horn neurons were made in CCI animals, as 
described previously[61]. Following halothane induction, the jugular vein and trachea 
were canulated and intravenous anaesthetic delivered: α-chloralose (0.6 mg/kg, 
Fisher) and urethane (1.2mg/kg, Sigma), with small supplementary doses of α-
chloralose as required throughout the experiment. Core body temperature was 
maintained at 37-38ºC by means of a thermostatically controlled heated blanket. The 
animal was placed in a stereotaxic frame, and the thoracolumbar spinal column was 
supported using three pairs of swan-necked clamps. A laminectomy was performed 
at L2-L5, and agar (2% in saline at 37oC) was delivered over exposed cord to 
increase mechanical stability. Above the recording region the agar and spinal cord 
dura were removed and liquid paraffin poured into the pool. Extracellular recordings 
were made from single multireceptive neurons in laminae I-IV through the centre 
barrel of a seven-barrelled glass microelectrode filled with 4M NaCl (tip-diameter 4-5 
mm, DC resistance 5-8 MΩ). The receptive fields of hair-follicle innervated neurons 
on the distal hindlimb were identified by an innocuous brush stimulus[61]. Icilin (200 
µM in water with 0.2% DMF) was applied peripherally to the receptive field of 
individual recorded neurons, and the effect on neuronal response to a rotating brush 
was recorded and analysed using Spike2 programme (Version 3.2, CED). The Group 
III mGluR antagonist UBP 1112 (20 mM in water), pH 8.5, and control 1M NaCl, pH 
8.5 were ionophoresed from the side barrels of the electrode using currents of 
between 20nA and 80nA (Neurophore BH2 ionophoresis system, Medical Systems, 
Great Neck, NY) to measure effects on neuronal response to icilin.  
Statistics 
All data were analysed for statistical significance using Sigmastat software (version 
2.03) with p values <0.05 being considered significant. Differences in thermal 
sensitivity between the paw ipsilateral to nerve injury and the contralateral paw were 
assessed using Student’s t-test. Any effect of drug treatment was analysed by One-
way Repeated Measures ANOVA followed by Dunnett’s post-hoc multiple 
comparisons test. The equivalent non-parametric tests for mechanical sensitivity 
were Wilcoxon rank test for ipsilateral:contralateral differences, and Friedman 
Repeated Measures ANOVA followed by Dunn’s test for changes from pre-drug 
control values. Western blot densitometric values were compared using the Wilcoxon 
test, immunohistochemistry cell counts were analysed by One-Way ANOVA, and 
electrophysiological spike frequencies were analysed by One-Way ANOVA on ranks. 
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Figure 1 Peripheral TRPM8 activation and moderate cooling are analgesic 
following CCI.   
A,B,C,E) Behavioural data from CCI animals, shown as mean ± SEM, each graph 
represents n of 6 animals. A) Paw withdrawal latency (PWL; s) to noxious heat and 
paw withdrawal threshold (PWT; mN/mm2) to mechanical stimuli before and following 
5 min paw immersion in a shallow 30oC water bath containing 80µM icilin or vehicle; 
¡: ipsilateral paw plus icilin, : ipsilateral + vehicle; n: contralateral plus icilin, n: 
contralateral plus vehicle, * indicates significant ipsilateral-contralateral differences, † 
indicates significant difference from pre-drug baseline (p<0.05). B) Concentration-
response curve for mean ± SEM percentage reversal of ipsilateral sensitisation for 
thermal (¡) or mechanical (¿) tests calculated over 10-15 min following paw 
immersion in 2.5-500µM icilin. C) Reversal of ipsilateral sensitisation by paw 
immersion in (-)-menthol at 4mM, and by higher concentrations of the less potent 
stereoisomers (+)-menthol and isomenthol (8 and 16mM). Values were calculated 
over 10-25 min following paw immersion from experiments as shown in A). † 
indicates significant differences from pre-drug baseline (p<0.05). D) Typical 
electrophysiological recording from the subpopulation of icilin-responsive C-fibre 
afferent fibres before, 2 min following topical application of icilin to the receptive field 
(peak effect) and 12 min later. E) Mechanical analgesia measured over 5 min 
following 5 min immersion of paws at the indicated temperature range. § denotes 
spontaneous withdrawal responses during the immersion period, * denotes 
significant difference from contralateral paw and † from pre-immersion baseline 
(p<0.05).  
 
Figure 2 TRPM8 immunoreactivity is present in DRG and spinal cord, arises 
from afferents and is increased ipsilateral to CCI. 
A) Immunoblots of DRG show whole gels with TRPM8 protein running at 128kDa and 
additional faint bands at approximately 170, 60 and 50 kDa, in normal rat DRG with 
specific knockdown of the 128 kDa band in DRG from antisense-treated animals. In 
additional controls, when the TRPM8 antibody was pre-incubated with membranes 
from TRPM8-expressing cells, the 128kDa immunoreactive band was removed, 
whereas sham-treatment had no effect. Blots additionally show GAPDH loading 
controls. TRPV1 expression (single band at ~90 kDa) was unaltered in DRGs from 
TRPM8 antisense-treated animals. Immunoblots for TRPM8 protein showed a clear 
increase in expression of the specific 128kDa band in DRG ipsilateral (‘ipsi’) to nerve 
injury compared to contralateral (‘con’) and naive DRG, with no change in GAPDH. 
Spinal cord (SC) whole lysates showed no discernable changes in TRPM8 levels, 
however, increased levels ipsilateral to nerve injury were seen in crude particulate 
fractions. B) Shows Western blots of DRGs from naïve or TRPM8 antisense-treated 
rats probed with the TRPM8 antibody used for immunohistochemistry in C)-F) below. 
Pretreatment of the antibody with the antigenic peptide or TRPM8 antisense 
treatment removed the single specific band at ^128 kDa. C) L5 spinal cord sections 
taken 8 days after dorsal rhizotomy were immunostained for peripherin (green) and 
TRPM8 (red) and showed marked reduction of both proteins ipsilateral to rhizotomy. 
D) Immunostaining for TRPM8 (red) and the neuronal marker NeuN (green) in spinal 
dorsal horn from CCI animals showed that TRPM8 was increased ipsilateral to CCI 
with no change in distribution, whereas NeuN levels were unchanged. Scale bar for 
C) and D) is 500µm.  E,F) Immunohistochemical colocalisation in DRG sections 
ipsilateral or contralateral to nerve injury and in naive animals of TRPM8 (red) with 
(E) NF-200 (green) or (F) peripherin (green). In naïve animals, TRPM8 is mainly 
located in peripherin-positive C-fibres with little or no apparent expression in 
myelinated (NF-200) cells. Ipsilateral to nerve injury, TRPM8 expression was 
increased markedly in small NF-200-positive cells, whereas a lesser increase in 
TRPM8:peripherin co-expression was also observed. Scale bar 50µm. The bar 
charts in E) and F) show the percentage co-expression (mean ± SEM) for 
TRPM8:NF-200 and TRPM8:peripherin  respectively; actual cell counts shown above 
columns. Statistically significant increases in the percentage co-expression values 
were seen in both cases ipsilateral to CCI, p<0.05 (*). 
 
Figure 3 Specific TRPM8 knockdown by antisense oligonucleotide prevents 
icilin-induced analgesia following CCI. 
A, B) Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold 
(PWT; mN/mm2) to mechanical stimuli are shown ipsilateral (¡) or contralateral (n) 
to CCI animals with antisense (n=12) or mis-sense (n=10) treatments.  Data show 
mean ± SEM. A) The analgesia normally elicited by topical icilin was not observed 
following antisense knockdown of TRPM8 receptor indicated by the persistence of 
significant ipsilateral-contralateral differences in PWL and PWT (* p<0.05). B) In 
contrast, following mis-sense treatment, icilin produced a significant reversal of CCI-
induced ipsilateral sensitisation in PWL and PWT responses in comparison to 
baseline values († p<0.05), as in untreated CCI animals (Fig 1A). C) Immunoblots of 
DRG tissue probed for TRPM8 and GAPDH protein levels following TRPM8 
antisense or mis-sense treatment. TRPM8 expression (and the increase in 
expression normally seen ipsilateral to CCI, Fig 2A) was selectively reduced by 
antisense, but not mis-sense infusion, whereas GAPDH levels were unchanged.  
 
Figure 4 Central TRPM8 activation is analgesic following CCI, whereas TRPA1 
activation is hyperalgesic.  
Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold 
(PWT, mN/mm2) to mechanical stimuli are shown ipsilateral (¡) or contralateral (n) 
to CCI * denotes significant ipsilateral-contralateral differences (* p<0.05). Data show 
mean ± SEM and each test represents n of 6 animals unless otherwise indicated.  
Rats were intrathecally injected at arrow. The TRPM8 activators, A) Icilin (10nmol), 
and B) (-)-menthol (200nmol) both significantly reversed ipsilateral thermal and 
mechanical sensitisation in comparison to pre-injection values († p<0.05). C) In 
contrast, intrathecal application of the TRPA1 activator, cinnamaldehyde (75nmol) 
produced bilateral hyperalgesia and allodynia in CCI animals. §(p<0.05) shows 
statistically significant increases in thermal and mechanical reflex responsiveness of 
both ipsilateral and contralateral paws. D) Shows that Ruthenium Red (0.25 nmol) 
inhibits cinnamaldehyde (75 nmol)-induced hypersensitivity, but not icilin (10 nmol)-
mediated analgesia, ipsilateral to CCI. Values are means ± SEM, n=4. Statistically 
significant changes in PWL/PWT values due to cinnamaldehyde or icilin compared to 
pre-drug baseline are shown as (§) and (†) respectively (p<0.05) and for Ruthenium 
Red-reversal of the effect of cinnamaldehyde (††, p<0.05). 
 
Figure 5 Icilin-induced analgesia following CCI is prevented by Group II and III 
mGluR antagonists. 
(A-D) Paw withdrawal latency (PWL, s) to noxious heat and paw withdrawal threshold  
(PWT, mN/mm2) to mechanical stimuli ipsilateral (¡) or contralateral (n) to CCI. Data 
represent mean ± SEM, with an n of 6 animals in each case. Rats were intrathecally 
injected (at arrow). Icilin (10nmol) was co-administered with A) the group II mGluR 
antagonist, LY 341495 (5nmol), B) the group III mGluR antagonist, UBP 1112 
(10nmol) or C) the opioid receptor antagonist, naloxone (25nmol). A, B) When either 
LY 341495 or UBP 1112 were co-administered with icilin, they abolished the 
analgesic effect of icilin as indicated by the persistence of sensitised (* p<0.05) 
PWT/PWL responses ipsilateral to nerve injury. C) naloxone co-administration with 
icilin did not prevent the icilin-induced analgesia seen in PWT and PWL responses 
ipsilateral to nerve injury († p<0.05). * indicates significant ipsilateral-contralateral 
differences, † indicates significant ipsilateral analgesic effect of drug (p<0.05). D) The 
analgesic effects of topically applied icilin (200µM at 30 oC) were also reversed by 
intrathecal injection of Group II/III mGluR antagonists.  The figure shows mean % 
reversal of the ipsilateral/contralateral difference in either PWL or PWT measured 
over 15-30 min following 5 min topical application of icilin, with or without concurrent 
intrathecal injection of LY 341495 (5nmol) or UBP 1112 (10nmol), or following mGluR 
antagonists alone. E) Typical extracellular recording of a single dorsal horn neuron 
ipsilateral to CCI, responding to continuous motorised brushing of the cutaneous 
receptive field on the hindpaw and the effects of icilin (200µM at 30 oC) topically 
applied to an adjacent area of the receptive field. Similar results were observed in 8 
out of 12 neurons with examples in both laminae III/IV and lamina I. Neuronal firing is 
displayed as action potentials per second (Hz) plotted against time. (i): brush-evoked 
firing in neurons ipsilateral to nerve injury was consistently inhibited by topically 
applied icilin, (ii): this effect was reversed by ionophoresis of UBP 1112 at 20-60nA, 
(iii): recovery was observed following removal of the UBP 1112 ejection current. 
Neurons contralateral to nerve injury were unaffected by icilin and topical vehicle had 
no effect. In addition, ionophoresis of UBP 1112 alone or saline current controls 
showed no discernable effect.  
 
Figure 6 Schematic representation of a possible mechanistic basis for TRPM8-
mediated-analgesia following CCI. 
In this simplified hypothetical model, activation of TRPM8 in a subpopulation of 
afferents, by icilin, menthol or moderate cooling leads to central synaptic release of 
glutamate which then acts through inhibitory Group II/III mGluR receptors located 
either pre-synaptically on injury-activated nociceptive afferents or perhaps also post-
synaptically on dorsal horn neurons, thereby attenuating neuropathic sensitisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Analgesic effects of topically administered icilin against neuropathic 
sensitisation revert at very high concentrations to a general nociceptive effect 
 
Reflex response sensitivity at different times after icilin application to paw 
Thermal PWL (s) 
Drug 
Concentration 
(µM) Naïve CCI Ipsi CCI Con 
Pre-drug 
Baseline 15.5 ± 0.2 9.7 ± 0.2 16.4 ± 0.2 
 15 mins 50 mins 15 mins 50 mins 15 mins 50 mins 
0 (vehicle) 15.1 ± 1.2 14.9 ± 0.8 9.8 ± 1.1 9.7 ± 0.9 15.2 ± 0.6 15.1 ± 0.7 
1000 15.1 ± 1.2 14.8 ± 0.9 16.4 ± 0.8† 8.6 ± 0.2 16.1 ± 0.5 15.2 ± 0.4 
2500 14.9 ± 0.3 13.2 ± 0.8 16.4 ± 0.9† 8.4 ± 0.6 16.8 ± 0.9 15.3 ± 0.7 
5000 15.3 ± 0.5 13.1 ± 0.7§ 16.7 ± 1.0† 7.2 ± 0.6§ 16.1 ± 0.9 13.4 ± 0.7§ 
Mechanical PWT (mN/mm2) 
 Naïve CCI Ipsi CCI Con 
Pre-drug 
Baseline 4830.6 ± 0.0 805.7 ± 26.3 4793.6 ± 37.5 
 15 mins 50 mins 15 mins 50 mins 15 mins 50 mins 
0 (vehicle) 4830.6 ± 0.0 4830.6 ± 0.0 805.7 ± 26.3 805.7 ± 26.3 4830.6 ± 0.0 4830.6 ± 0.0 
1000 4830.6 ± 0.0 4830.6 ± 0.0 702.8 ± 185.3 702.8 ± 185.3 4530.1 ± 300.5 4530.1 ± 300.5 
2500 4830.6 ± 0.0 4830.6 ± 0.0 651.9 ± 193.0 651.9 ± 193.0 4454.9 ± 245.9 4454.9 ± 245.9 
5000 3828.6 ± 316.8§ 4830.6 ± 0.0  412.2 ± 24.3§ 736.0 ± 26.3 2040.2 ± 115.2§ 4830.6 ± 0.0  
 
Significant effects of drug on reflex responses are indicated: † denotes significant 
increase from baseline indicating analgesic effect of icilin, § denotes significant 
decrease from baseline values indicating hyperalgesic effects.   
 
 
 
 
 
 
 
Table 2: Reversal of sensitisation by intrathecal icilin administration in 
different pain models 
 
 
Pain Model 
PWL (s) 
difference 
from 
control  
(no drug) 
PWL (s) 
difference 
from 
control  
(+ icilin) 
Mean % 
reversal of  
thermal 
sensitisation 
(after 15-
30mins) 
PWT (mN/mm2) 
difference from 
control  
(no drug) 
PWT 
(mN/mm2) 
difference from 
control  
(+ icilin) 
Mean % 
reversal of  
mechanical 
sensitisation 
(after 15-
30mins) 
CCI 5.9 ± 0.9 * 0.9 ± 1.2 † 84.7 ± 6.0  3347.4 ± 126.3 * 775.4 ± 467.7 † 76.8 ± 5.3 
CFA 4.7 ± 0.9 * 1.6 ± 1.6 † 66.0 ± 7.5 2975.6 ± 245.5 * 1707.6 ± 149.9 † 42.6 ± 2.8 
Lysolecithin 7.8 ± 1.0 * 2.4 ± 1.2 †  69.2 ± 5.1 3003.8 ± 182.4 * 1102.5 ± 422.5 † 63.3 ± 6.4 
Cinnamaldehyde  
(intrathecal) 5.9 ± 0.9 * 0.5 ± 1.8 † 91.5 ± 4.1 2022.6 ± 375.4 * 150.3 ± 125.2 † 92.6 ± 2.8 
Cinnamaldehyde 
(topical) 5.0 ± 1.5 * 0.4 ± 1.6 † 
 
 
92.0 ± 6.1 1002.0 ± 316.8 * 0.0 ± 0.0 † 100.0 ± 0.0 
 
 
* Significant ipsilateral-contralateral differences in surgical pain models or, in the 
case of cinnamaldehyde-induced responses, differences from prior baseline are 
indicated (*, p<0.05). Significant icilin (10nmol, i.t.)-induced reversal of sensitisation 
is indicated (†, p<0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Material 
 
Western blots 
Ipsilateral or contralateral L4-L6 dorsal root ganglia (DRG) were taken from CCI 
animals (n=6), and from naive animals. DRG were also taken from naïve and CCI 
animals that had undergone either antisense or mis-sense treatment to knockdown 
TRPM8 expression (n=5). Spinal cord from CCI animals was hemisected and 
samples from naïve animals were also processed. Individual samples were weighed 
and homogenised immediately upon removal. For whole lysate preparations, tissue 
was homogenised in 20 volumes of Laemmli lysis buffer (Tris (tris-
hydroxymethylaminoethane, 50 mM, pH 7.4 with 5% mercaptoethanol and 2% 
sodium dodecyl sulphate (SDS)), boiled for 5 min and frozen. In some cases with 
spinal cord samples, a crude particulate fraction was prepared to obtain relative 
enrichment of membrane-bound compared to cytosolic proteins. Tissue was 
homogenised in 20 volumes of ice-cold Tris buffer (50 mM, pH 7.4, containing 1% 
protease inhibitor cocktail III (Calbiochem, Merck Biosciences Ltd., Nottingham, UK) 
and then centrifuged at 11000g for 45 min at 4oC, before solubilising the pellet in 
Laemmli buffer. Western blotting was carried out as described previously[57]. Proteins 
were separated by SDS-PAGE on 3-8% Tris-acetate gradient gels using the 
(NuPage System, Invitrogen Ltd., Paisley, UK). Blots were incubated with rabbit 
polyclonal antibodies to TRPM8 (either an antibody raised against TRPM8 residues 
278-292 and 1090-1104 (human); 1:500; Abcam Ltd., Cambridge, UK or occasionally 
an antibody raised against TRPM8 residues 656-680 (rat); 1:100; Phoenix Peptides, 
Belmont, CA, USA), a rabbit polyclonal antibody to TRPV1 (1:250, Chemicon 
International Ltd, Harrow, UK) or a mouse monoclonal antibody to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, 1:750; Chemicon) and immunoreactive bands 
were detected by peroxidase-linked secondary antibody and enhanced 
chemiluminescence. Quantitative densitometry analysis of protein bands was 
performed using the ScanAnalysis (Elsevier) programme.  
Antigen preabsorbtion controls were carried out to assess the specificity of the 
TRPM8 antibodies, by preincubating the antibody with either membrane preparations 
from cells heterologously expressing TRPM8 (or control) or the antigenic peptide (or 
control). COS7 cells were transfected with human TRPM8 in pCMV6-XL4 expression 
plasmid or empty vector (OriGene Technologies Inc., Rockville, MD, USA) using 
GeneJuice Reagent (Novagen, Merck Biosciences Ltd., Nottingham, UK) and used 
48 h later.  Cells were scraped into ice-cold phosphate-buffered saline (PBS) 
containing 1% protease inhibitor cocktail III (Calbiochem) and homogenised (Ystral 
homogeniser) before centrifuging at 1000g for 10 min (and discarding the low speed 
pellet).  The supernatant was then centrifuged at 48,000g for 30 min and the pellet 
from this was resuspended in primary antibody buffer (2% BSA, 0.1% Tween-20 in 
PBS). Anti-TRPM8 (residues 278-292 and 1090-1104; human) antibody was added 
to TRPM8-expressing or control membrane suspensions and rolled at 4oC for 16 h 
prior to use.  In the case of the anti-TRPM8 (residues 656-680; rat) antibody, the 
antigenic peptide was available, so aliquots of the antibody were preincubated with 
the peptide (dissolved at a stock concentration of 1mg/180 µl in PBS) and used at a 
ratio of 5 µg peptide:1 µg antibody, by rolling at 4oC for 16 h.  Control aliquots were 
treated with PBS alone.  
 
Immunohistochemistry 
DRGs and spinal cord from lumbar segments L5/6, ipsilateral or contralateral to CCI 
or from naïve or rhizotomised animals were taken. Tissue was snap frozen in liquid 
nitrogen and embedded in OCT (Cell Path plc. Powys. Wales, UK). Cryostat sections 
(15µm) were cut and thaw-mounted on poly-L-lysine slides (Merck-BDH). Slides 
were blocked in 10% normal goat serum, 0.1M PBS, pH 7.4, 0.2% Triton X-100, 4% 
fish skin gelatin for 1 h at room temperature and incubated overnight with appropriate 
primary antibodies in buffer (0.1 M PBS, pH 7.4, 0.2% Triton X-100, 4% normal goat 
serum, 4% fish skin gelatin). Antibodies used were: rabbit polyclonal anti-TRPM8, 
raised against residues 656-680 (rat) (Phoenix Peptides, 1:450), mouse monoclonal 
anti-NF-200 (Sigma, 1:1000), mouse monoclonal anti-peripherin (Chemicon, 1:250), 
mouse monoclonal anti-NeuN (Chemicon, 1:500). In experiments to assess 
specificity of the TRPM8 antibody used for immunohistochemistry, antibody aliquots 
were pre-incubated with the antigenic peptide or PBS control, as above. Slides were 
washed, incubated with appropriate fluorescent secondary antibodies in the same 
buffer excluding Triton X-100, (goat anti-rabbit AlexaFluor 568 1:750, goat anti-
mouse AlexaFluor 488, 1:500, Molecular Probes, OR, USA), washed, stained with 
To-Pro nuclear stain (1:1000, To-Pro-3-iodide, Molecular Probes), coverslipped and 
sealed. Control sections were processed as above omitting the primary antisera. 
Sections were visualised using a Leica TCSNT confocal microscope (Leica 
Microsystems GMBH, Germany. Image analysis was performed with Image Tool 
software (UTHSCSA Image Tool Version 3.0) and illustrations prepared using Adobe 
Photoshop 7.0. Cell counts were performed on five to eight randomly selected DRG 
sections (separation of 100 µm) from each of three animals in each group, and only 
neurons with clear nuclei were counted. Results were expressed as the proportion of 
TRPM8-labelled cells per total number of peripherin/NF-200 labelled cells from all 
sections.  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
